8-K: MariMed Reports Mixed Q1 2024 Results: Revenue Up, Profitability Down

MariMed Inc. announced a revenue increase for Q1 2024, but experienced a decrease in profitability compared to the same period last year.

Summary

• MariMed Inc. reported its financial results for the first quarter of 2024, showing a revenue increase to $37.9 million from $34.4 million in the same period last year.
• The company's GAAP gross margin decreased slightly from 45% to 43%, and non-GAAP gross margin also saw a decrease from 46% to 44%.
• The company experienced a GAAP net loss of $1.3 million, compared to a loss of $0.7 million in the first quarter of 2023.
• Non-GAAP net loss was $0.6 million, a decrease from a $0.3 million profit in the prior year.
• Non-GAAP adjusted EBITDA decreased to $4.7 million from $7.1 million, with the adjusted EBITDA margin dropping from 21% to 12%.
• The company's wholesale business experienced significant growth during the quarter.
• MariMed reaffirmed its full-year 2024 financial targets, projecting revenue growth of 5% to 7% and non-GAAP adjusted EBITDA growth of 0% to 2%, with capital expenditures of $10 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with revenue growth offset by decreased profitability. While there are positive developments in expansion and partnerships, the overall financial performance is weaker than the previous year, leading to a neutral sentiment.

Positives

• Revenue increased year-over-year, reaching $37.9 million in Q1 2024.
• The company's wholesale business showed strong growth.
• MariMed expanded its market presence through acquisitions and partnerships.
• The company has maintained 17 consecutive quarters of positive adjusted EBITDA.
• The company is on track with its strategic plan and financial targets.

Negatives

• GAAP net loss increased to $1.3 million from $0.7 million in the same quarter last year.
• Non-GAAP net income decreased from a profit of $0.3 million to a loss of $0.6 million.
• Non-GAAP adjusted EBITDA decreased to $4.7 million from $7.1 million.
• The adjusted EBITDA margin decreased from 21% to 12%.
• Both GAAP and non-GAAP gross margins decreased slightly compared to the previous year.

Risks

• The company's financial results are subject to risks and uncertainties, including changes in customer spending and the ability to retain key personnel.
• Integration of acquired companies could cause disruptions.
• Changes in demand for the company's services and products, changes in the law and its enforcement, and changes in the economic environment could impact results.
• The company's non-GAAP financial measures may not be directly comparable to those of other companies.

Future Outlook

MariMed's full year 2024 financial targets are based on organic growth of its existing operating assets and do not include new revenue-generating projects requiring regulatory approvals. The company projects revenue growth of 5% to 7% and non-GAAP adjusted EBITDA growth of 0% to 2%.

Management Comments

• Jon Levine, Chief Executive Officer, stated that the company is on track with its strategic plan and financial targets.
• Jon Levine highlighted the tremendous growth in the wholesale business as a key positive for the quarter.
• Jon Levine mentioned that MariMed outperformed its competition in every market in which it operates, including Illinois.

Industry Context

The cannabis industry is experiencing growth, but also increased competition and regulatory changes. MariMed's focus on expanding its wholesale business and strategic acquisitions aligns with industry trends, but the decrease in profitability highlights the challenges of maintaining margins in a competitive market.

Comparison to Industry Standards

• While MariMed's revenue growth is positive, the decrease in profitability metrics such as gross margin and adjusted EBITDA margin is concerning when compared to other multi-state cannabis operators.
• Companies like Curaleaf and Green Thumb Industries, while larger, have shown more robust profitability in recent quarters, indicating that MariMed may need to improve its operational efficiency.
• The expansion into new markets like Maryland is a positive step, but the company needs to ensure these acquisitions contribute positively to the bottom line.
• The partnership with Boston music venues is a unique marketing strategy, but its impact on revenue and profitability remains to be seen.

Stakeholder Impact

• Shareholders may be concerned about the decrease in profitability despite revenue growth.
• Employees may be impacted by the company's performance and strategic changes.
• Customers will benefit from the expanded availability of MariMed's products.
• Suppliers may see increased business due to the company's growth.

Next Steps

• MariMed management will host a conference call on May 9, 2024, to discuss the Q1 2024 results.
• The company plans to open its newly acquired dispensary in Upper Marlboro, Maryland, and commence adult-use sales upon regulatory approval.
• MariMed will continue to focus on organic growth and the implementation of its strategic plan.

Key Dates

Keywords

cannabis, MariMed, financial results, Q1 2024, EBITDA, revenue, wholesale, dispensary, acquisition, non-GAAP